NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026
NeoGenomics, Inc. announced it will release its first quarter 2026 financial results after market close on Tuesday, April 28, 2026. The company will host a webcast and conference call at 4:30 p.m. ET to discuss the results and recent highlights. This marks a new schedule for quarterly calls, which will now take place after market close.
NeoGenomics to Report Q1 2026 Earnings on April 28
NeoGenomics, a leading provider of cancer-focused genetic testing, announced it will report its first-quarter 2026 financial results on Tuesday, April 28, 2026. The company will host a conference call and webcast to discuss these results on the same day at 8:30 a.m. Eastern Time. This report is crucial for investors and industry analysts to understand NeoGenomics' performance and trends in the oncology testing market.
Aberdeen Group plc Buys 1,006,676 Shares of NeoGenomics, Inc. $NEO
Aberdeen Group plc significantly increased its stake in NeoGenomics, Inc. by 127.1% in Q4, purchasing over 1 million shares. This brings their total holdings to nearly 1.8 million shares, valued at approximately $21.16 million, representing about 1.39% of the company. Despite insider selling by COO Warren Stone, institutional ownership in NeoGenomics stands at 98.50%, while analysts currently hold a "Hold" rating with a consensus target price of $11.86.
NeoGenomics Inc Stock: Precision Oncology Leader Faces Growth Challenges in Competitive Diagnostics
NeoGenomics Inc, a prominent provider of cancer genetics testing, is navigating revenue pressures and profitability challenges in the evolving oncology diagnostics market. Despite its specialization and growth in areas like immunotherapy and targeted drugs, the company faces competition, reimbursement pressures, and profitability hurdles. Investors are monitoring its strategic initiatives, including automation and test portfolio expansion, for potential recovery and long-term growth.
NeoGenomics (NEO) CEO exercises RSUs and uses shares to cover taxes
NeoGenomics Inc.'s CEO, Anthony P. Zook, exercised 140,498 restricted stock units (RSUs) on April 1, 2026, and simultaneously used 45,453 common shares to cover associated tax obligations. Post-transaction, he directly holds 133,111 common shares and indirectly holds 18,900 shares through a living trust. The filing also details his remaining substantial stock options and newly granted RSUs and options that vest ratably over three years.
NeoGenomics (NEO) COO nets shares after 17,562-unit RSU vesting
NeoGenomics Inc.'s President & Chief Operating Officer, Warren Stone, reported the vesting and exercise of 17,562 restricted stock units (RSUs) on April 1, 2026. Following the conversion into common stock at an exercise price of $0.00 per share, 6,911 shares were disposed of for tax withholding. Stone now directly holds 158,365 shares of NeoGenomics common stock, in addition to various outstanding stock option, RSU, and performance stock unit awards.
NeoGenomics Inc stock: Precision oncology leader facing growth hurdles
NeoGenomics Inc. specializes in precision oncology diagnostics, holding a critical niche in cancer genetics testing with laboratories across the U.S. While the company operates in a high-growth sector and strategically serves both clinical oncology and pharmaceutical drug development, it faces significant profitability hurdles with ongoing net losses due to heavy investments. North American investors are advised to monitor its progress toward profitability and navigate the competitive diagnostics market before making investment decisions.
NeoGenomics Inc stock: Precision oncology leader facing growth hurdles
NeoGenomics Inc. specializes in precision oncology diagnostics, offering cancer genetics testing and pharmaceutical services, primarily in the U.S. While the company operates in a high-growth sector driven by rising cancer rates and advancing therapies, it faces profitability hurdles with persistent net losses due to heavy investments. Investors are advised to watch their growth trajectory, market share gains in precision oncology, and the path to profitability, balancing growth prospects against execution risks and competitive pressures.
NeoGenomics Inc Stock: Precision Oncology Leader Faces Growth Challenges in Competitive Diagnostics
NeoGenomics Inc, a prominent provider of cancer genetics testing, faces revenue and profitability challenges amidst a competitive oncology diagnostics market. Despite these hurdles, analyst targets suggest potential upside for the stock. The company focuses on precision medicine solutions through clinical and pharma services, leveraging its specialized expertise in inherited cancer diagnostics and next-generation sequencing.
Neogenomics Inc Today's Market Trends | NEO Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey
This article provides an analysis of Neogenomics Inc (NEO) stock, highlighting its healthy fundamentals, high growth potential, and strong institutional ownership. Despite recent weak market performance, the company shows promising technicals and is currently considered fairly valued within its industry. Analysts have given it a "Buy" rating with a target price indicating significant upside.
Avoiding Lag: Real-Time Signals in (NEO) Movement
This article from Stock Traders Daily provides a technical analysis of Neogenomics Inc. (NYSE: NEO), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It details AI-generated trading strategies for different risk profiles, including long, momentum breakout, and short positions, along with multi-timeframe signal analysis indicating support and resistance levels. The report emphasizes the use of real-time signals and institutional-grade analysis for informed trading decisions.
NeoGenomics Inc Stock: A Key Player in Cancer Diagnostics Amid Evolving Healthcare Demands
NeoGenomics Inc is a key player in the oncology diagnostics sector, providing comprehensive laboratory testing services essential for cancer diagnosis and treatment decisions. The company's business model focuses on high-complexity genetic tests and strategic partnerships, positioning it for growth amid rising cancer incidence rates and advancements in precision medicine. While facing competition and reimbursement pressures, NeoGenomics offers investors exposure to defensive healthcare growth and resilience in a specialized, high-demand market.
NeoGenomics Inc Stock: A Key Player in Cancer Diagnostics Amid Evolving Healthcare Demands
NeoGenomics Inc (NASDAQ: NEO) plays a crucial role in the cancer diagnostics sector by providing specialized oncology testing services essential for precision medicine. The company focuses on innovation in next-generation sequencing and companion diagnostics, positioning itself competitively against larger labs through specialization and proprietary assays. Investors can find long-term growth potential in NeoGenomics due to its alignment with rising cancer incidence rates and its service-oriented model delivering steady cash flows in the robust healthcare growth sector.
Tudor Investment Corp ET AL Sells 320,361 Shares of NeoGenomics, Inc. $NEO
Tudor Investment Corp ET AL significantly reduced its stake in NeoGenomics, Inc. by selling 320,361 shares, bringing its total holdings to 375,351 shares valued at approximately $2.9 million. The medical research company recently reported stronger-than-expected quarterly earnings, beating analyst estimates for both EPS and revenue. Despite this, the stock saw a recent decline, opening down 7.3% at $7.19, and holds a consensus analyst rating of "Hold" with a target price of $11.86.
Tudor Investment Corp ET AL Sells 320,361 Shares of NeoGenomics, Inc.
Tudor Investment Corp ET AL has reduced its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 46% during the third quarter of 2026, selling 320,361 shares. The hedge fund now owns 375,351 shares of the medical research company, worth approximately $2.9 million. This transaction highlights a significant shift in the investment landscape for NeoGenomics and the healthcare sector, prompting investors and analysts to monitor future changes in institutional holdings and company performance.
Vanguard files 13G/A: NeoGenomics (NEO) ownership shows 0 shares
Vanguard has filed a Schedule 13G/A amendment for NeoGenomics (NEO), reporting 0 shares beneficially owned. This change is due to an internal realignment within The Vanguard Group, wherein certain subsidiaries will now report their holdings separately, in reliance on SEC Release No. 34-39538. The filing indicates Vanguard's ownership in NeoGenomics is 0%.
NeoGenomics slides more than 5% despite fourth-quarter earnings beat
This article is incomplete and contains no meaningful content. Therefore, a summary cannot be provided.
Medicare Coverage for PanTracer LBx Liquid Biopsy Could Be A Game Changer For NeoGenomics (NEO)
NeoGenomics recently secured Medicare coverage for its PanTracer LBx liquid biopsy test, which is expected to broaden access to noninvasive genomic testing for Medicare beneficiaries and reinforce the role of liquid biopsy in therapy selection. This coverage supports NeoGenomics' precision oncology platform and offers a significant near-term catalyst for broader liquid biopsy uptake. However, the company still faces risks from high fixed costs and potential underutilization if test volumes don't meet expectations, despite an optimistic revenue forecast for 2028.
NEO Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an in-depth financial analysis of Neogenomics Inc (NEO), detailing its revenue breakdown, profitability margins, and a comparison with competitors AZTA and TDOC. NEO primarily generates revenue from Clinical Services-Client direct billing, contributing 70.4% of its sales. The company exhibits a gross margin of 43.83% but reports negative operating and net margins, alongside a negative Return on Equity.
Medicare Coverage for PanTracer LBx Liquid Biopsy Could Be A Game Changer For NeoGenomics (NEO)
NeoGenomics announced Medicare coverage for its PanTracer LBx liquid biopsy test, which is expected to broaden access to noninvasive genomic testing for Medicare beneficiaries and potentially transform the company's investment narrative. While this coverage strengthens NeoGenomics' precision oncology positioning, investors should still consider the risks associated with high fixed costs and potential slower-than-expected volume growth. The company's future revenue and earnings are projected to grow, with a fair value estimate suggesting significant upside to its current price.
Medicare Coverage for PanTracer LBx Liquid Biopsy Could Be A Game Changer For NeoGenomics (NEO)
NeoGenomics recently secured Medicare coverage for its PanTracer LBx liquid biopsy test, which is expected to broaden access to genomic testing for Medicare beneficiaries and bolster the company's precision oncology strategy. While this coverage is a positive catalyst for NeoGenomics, investors should remain mindful of risks such as high fixed costs and potential underutilization of capacity. The company projects significant revenue and earnings growth by 2028, with a fair value estimate suggesting an 81% upside.
NeoGenomics (NEO) Launches RaDaR ST to Capture Share in $20B MRD Market
NeoGenomics (NEO) has launched RaDaR ST, a new circulating tumor DNA assay designed for detecting molecular residual disease (MRD) across various solid tumor types. This innovative test aims to capture a significant share of the rapidly growing $20 billion MRD market, which is currently less than 10% penetrated. RaDaR ST provides patient-specific molecular insights, enabling earlier detection of residual disease and recurrence, and has already received Medicare approval for its initial indications.
NeoGenomics, Inc. (NASDAQ: NEO) Q4 2025 earnings call transcript
This document is an earnings call transcript for NeoGenomics, Inc. (NASDAQ: NEO) for their Q4 2025 financial results. It contains the detailed discussions from the company's conference call regarding their performance.
11 Most Buzzing Stocks to Buy with the Highest Upside Potential
NeoGenomics Inc. (NASDAQ: NEO) is highlighted as one of the most buzzing stocks with high upside potential, following the launch of its RaDaR ST assay. This new diagnostic tool targets the rapidly growing molecular residual disease (MRD) market, estimated at over $20 billion, by offering early detection of residual disease and recurrence in cancer patients. The advanced assay uses whole-exome sequencing and has received Medicare approval, significantly expanding NeoGenomics' oncology portfolio.
NeoGenomics, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Challenges
NeoGenomics, Inc. (a small-cap pharmaceutical and biotechnology company) has revised its evaluation due to market fluctuations and performance challenges. The stock has shown recent price increases but significant volatility over the past year, underperforming the S&P 500 with a year-to-date return of -29.93% and a three-year decline of 57.63%. Technical indicators present mixed signals, with a bearish MACD weekly but mildly bullish monthly, and varying insights from RSI, Bollinger Bands, moving averages, and KST.
Assessing NeoGenomics (NEO) Valuation After Recent Share Price Weakness
NeoGenomics (NEO) has experienced recent share price weakness, dropping 27.59% over the last 30 days, despite a narrative fair value of $14.81 suggesting it is 44.4% undervalued compared to its current price of $8.24. While the launch of PanTracer is expected to boost competitiveness, a high P/S ratio of 1.5x contrasts with the undervaluation narrative, indicating potential valuation risk. Investors are encouraged to review the company's financials for themselves to weigh both the bullish and cautious signals.
NEO NeoGenomics, Inc. Maintained: Cowen Buy, William Blair Market Perform Mar 2026
On March 16, 2026, analysts provided updated ratings for NeoGenomics, Inc. (NEO), with Cowen & Co. maintaining a Buy rating, citing potential 3-4% revenue increase from reimbursement shifts, and William Blair maintaining Market Perform based on a positive catalyst that doesn't yet change the medium-term outlook. Both firms kept their previous ratings, showing analysts are observing catalysts rather than making aggressive revisions. Meyka AI currently rates NEO with a 'B' grade, encouraging investors to use this and other reports alongside their own research.
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
NeoGenomics announced that its PanTracer™ LBx test secured Medicare coverage from the Centers for Medicare & Medicaid Services’ MolDX program. This approval will allow Medicare patients with advanced solid tumors to access the blood-based comprehensive genomic profiling test for therapy selection and clinical trial enrollment. The company views this as a major step in making precision oncology more accessible, particularly in community settings.
NeoGenomics Gets Dismissal of Cancer Test Misrepresentation Suit
A New York federal district court has dismissed a lawsuit against NeoGenomics Inc. and its executives. The suit alleged the company falsely promoted its products as a "one-stop-shop" for multiple cancer gene testing. The judge ruled that the plaintiff failed to provide sufficient particularized facts to prove NeoGenomics intentionally made misleading statements in violation of securities laws.
NeoGenomics Gets Dismissal of Cancer Test Misrepresentation Suit
A New York federal district court dismissed a lawsuit against NeoGenomics Inc. and its executives, which alleged they misrepresented the company's cancer testing products. The judge ruled that the plaintiff, Daniel Goldenberg, failed to provide sufficient particularized facts to prove that NeoGenomics intentionally made misleading statements in violation of securities laws. The complaint did not adequately show that the defendants' statements or omissions were made recklessly or with fraudulent intent.
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
NeoGenomics announced that its PanTracer LBx test has received Medicare coverage through CMS's MolDX program. This decision expands access to the blood-based comprehensive genomic profiling test for Medicare patients with advanced solid tumors, enabling more personalized treatment strategies and clinical trial enrollment support. The PanTracer LBx test provides actionable biomarker information from over 500 genes within a seven-day turnaround, reinforcing the clinical value and broader adoption of liquid biopsy in oncology.
NeoGenomics test gains Medicare coverage for cancer care
NeoGenomics Inc. has announced that its PanTracer LBx test for oncology diagnostics has received Medicare coverage through the Centers for Medicare & Medicaid Services’ Molecular Diagnostics Services Program. This blood-based genomic profiling test aids physicians in identifying treatment options and clinical trial opportunities for patients with advanced solid tumors. The coverage is expected to expand access to precision oncology testing for Medicare patients and support broader use of liquid biopsy diagnostics in cancer care.
Neogenomics stock gets MolDX reimbursement for cancer test
Neogenomics Inc. (NASDAQ:NEO) has received MolDX reimbursement for its PanTracer LBx CGP test, with each test reimbursed at $3,289, effective March 10. This reimbursement provides upside to current guidance, as it includes three weeks of first-quarter and a full second-quarter reimbursement not previously accounted for. Analysts predict the company will become profitable this year, further supported by recent strong Q4 2025 earnings and increased coverage for its PanTracer LBx test by the Centers for Medicare & Medicaid Services.
Neogenomics Inc - Pantracer Lbx Test Receives Medicare Coverage Under CMS Moldx Program
Neogenomics Inc. (NEO) announced that its Pantracer Lbx Test has received Medicare coverage under the CMS Moldx Program. This development was reported by Reuters, highlighting a strategic and business product update for the company.
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
NeoGenomics announced that its PanTracer™ LBx test, a blood-based comprehensive genomic profiling (CGP) test for advanced solid tumors, has received Medicare coverage. This decision, under CMS's MolDX program, significantly increases access to precision oncology for Medicare patients, enabling therapy selection and clinical trial enrollment. The test offers actionable biomarker information from a simple blood draw with a seven-day turnaround, reinforcing the clinical value and broader adoption of liquid biopsy in cancer care.
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
NeoGenomics announced that its PanTracer™ LBx test, a comprehensive liquid biopsy for advanced solid tumors, has received Medicare coverage from CMS's MolDX program. This coverage will make the test more accessible to Medicare patients, enabling physicians to utilize timely, personalized treatment strategies. The PanTracer LBx test offers actionable biomarker information from a blood draw, evaluating over 500 genes within a seven-day turnaround, supporting therapy selection and clinical trial enrollment.
Silverback Asset Management LLC Invests $1.55 Million in NeoGenomics, Inc. $NEO
Silverback Asset Management LLC recently acquired a new position in NeoGenomics, Inc. ($NEO), purchasing 201,313 shares valued at approximately $1.55 million in Q3, representing about 0.16% ownership. This comes amid mixed institutional investor activity and an insider sale by COO Warren Stone of 22,128 shares. Analysts currently have a consensus "Hold" rating on NeoGenomics with an average target price of $11.86, despite the company recently beating Q4 revenue and EPS estimates.
NeoGenomics (NASDAQ:NEO) Stock Price Down 7.9% - Should You Sell?
NeoGenomics (NASDAQ:NEO) stock declined 7.9% to $7.87 on Thursday despite beating quarterly estimates with EPS of $0.06 and revenue of $190.17 million. The company remains unprofitable, with analysts forecasting a negative EPS for the fiscal year. Wall Street analysts maintain a consensus "Hold" rating with an average target price of $11.86, while institutional ownership is high and insiders have reduced their positions.
Greenhouse Funds LLLP Acquires 789,510 Shares of NeoGenomics, Inc. $NEO
Greenhouse Funds LLLP significantly increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 10.6%, acquiring an additional 789,510 shares, bringing its total holdings to over 8.2 million shares valued at $63.46 million. This makes NeoGenomics the fund's 22nd largest holding, representing approximately 2.3% of its portfolio. NeoGenomics, a medical research company specializing in cancer-focused genetic testing, reported a 10.6% increase in quarterly revenue and an EPS of $0.06, beating analyst estimates, despite remaining unprofitable.
NeoGenomics (NEO) accounting chief granted new options and RSUs
NeoGenomics Inc.'s Chief Accounting Officer, Greg D. Aunan, received new equity awards on March 1, 2026, consisting of 36,825 stock options and 22,889 restricted stock units (RSUs). Both the options and RSUs have a $0.00 exercise/acquisition price and vest ratably over the first three anniversary dates of the grant. Once vested and converted, the common shares are not subject to expiration.
GW&K Investment Management LLC Cuts Stock Position in NeoGenomics, Inc. $NEO
GW&K Investment Management LLC significantly reduced its stake in NeoGenomics (NASDAQ:NEO) by 15.8% in Q3, selling 392,091 shares and now holding 2,082,885 shares valued at approximately $16.08 million. This comes as NeoGenomics reported better-than-expected Q3 earnings with $0.06 EPS and $190.17 million in revenue, despite remaining unprofitable overall. Analysts currently have a mixed outlook on the stock, with an average "Hold" rating and price target of $11.86, while the stock trades around $8.96.
Vanguard Group Inc. Has $107.34 Million Stock Position in NeoGenomics, Inc. $NEO
Vanguard Group Inc. decreased its stake in NeoGenomics, Inc. by 1.6% in the third quarter, reducing its holdings to 13,903,735 shares, valued at approximately $107.34 million, representing a 10.75% ownership. Other institutional investors also adjusted their positions, and company COO Warren Stone sold 22,128 shares. NeoGenomics surpassed Q4 revenue and EPS estimates, though the company remains unprofitable and holds a "Hold" consensus analyst rating with a target price of $11.86.
NeoGenomics, Inc. $NEO Shares Sold by Segall Bryant & Hamill LLC
Segall Bryant & Hamill LLC reduced its stake in NeoGenomics (NASDAQ:NEO) by 23.1% in Q3, selling over half a million shares, though it still holds 1.8 million shares valued at $14.02 million. Additionally, NeoGenomics COO Warren Stone sold 22,128 shares for $276,600. The company reported strong Q3 earnings, beating analyst estimates with $0.06 EPS and $190.17 million in revenue, an increase of 10.6% year-over-year, despite remaining unprofitable with a negative net margin.
A Look At NeoGenomics (NEO) Valuation After The RaDaR ST Assay Launch
NeoGenomics (NEO) has launched RaDaR ST, a new circulating tumor DNA assay, which has drawn attention to its stock. Despite recent product launches and updated guidance, the stock's near-term momentum is fading, though its long-term shareholder return is positive. The article explores the valuation, noting that while analysts widely consider it undervalued based on future earnings potential, current P/S multiples suggest it is richly priced compared to benchmarks.
NeoGenomics Stock Price Drops Below 200-Day Average
Shares of NeoGenomics, Inc. (NASDAQ:NEO) dropped below their 200-day moving average on Monday, trading as low as $9.29 and closing at $9.50. This dip signals potential concerns among investors and analysts regarding the company's performance, despite its leading position in cancer-focused genetic and molecular testing services. Various analysts have issued mixed ratings, with five recommending Buy, eight Hold, and one Sell.
Major equity grants to NeoGenomics (NEO) CEO Anthony P. Zook
NeoGenomics Inc. CEO Anthony P. Zook received significant equity awards on March 1, 2026, including 675,676 stock options and 406,918 restricted stock units. These awards, detailed in a Form 4 SEC filing, are designed as premium-price options and RSUs that vest ratably over three years. This compensation structure aims to align the CEO's incentives with long-term company performance and shareholder value.
Equity awards expand NeoGenomics (NEO) EVP Olivo’s stock-based pay
NeoGenomics Inc.'s Executive Vice President and General Counsel, Alicia C. Olivo, received new equity awards on March 1, 2026. These awards include 147,804 stock options and 89,013 restricted stock units, both granted at an exercise/issue price of $0.00 per share. The stock options are premium-priced, set at 110% of the closing share price on February 27, 2026, and both types of awards vest in equal installments over the first three anniversaries of the grant date.
NeoGenomics (NASDAQ:NEO) Stock Price Crosses Below 200-Day Moving Average - Here's What Happened
NeoGenomics (NASDAQ:NEO) stock has fallen below its 200-day moving average, trading at $9.50 with a volume of 1.77 million shares. Despite exceeding recent earnings estimates with an EPS of $0.06 and revenue of $190.17 million, the company remains unprofitable. Analysts hold a consensus "Hold" rating with an average target price of $11.86, while institutional ownership is high and insider selling has occurred.
NeoGenomics (NEO) CFO Abhishek Jain granted options and RSUs
NeoGenomics Inc.'s new Chief Financial Officer, Abhishek Jain, has reported his initial equity grants. On January 13, 2026, Jain was granted 183,578 stock options and 110,088 restricted stock units (RSUs), which will vest ratably over three years. These grants represent his initial beneficial ownership in the company, with the underlying common shares not subject to expiration once vested.
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
NeoGenomics has launched RaDaR ST, a circulating tumor DNA (ctDNA) assay designed for detecting molecular residual disease (MRD) across various solid tumor types. The test offers high sensitivity and specificity by using patient-specific, tumor-informed panels to identify trace amounts of tumor DNA. This advancement aims to provide clinicians with earlier detection of recurrence and more informed treatment decisions, addressing a significant and growing market need in oncology diagnostics.
